Chemokine mutants in the treatment of multiple sclerosis
US7402303B2 · kind B2 · utility
0Cited by
1References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 3, 2001 |
| Grant date | Jul 22, 2008 |
| Priority date | — |
| Expiry date | Feb 28, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Mutants of CC chemokines, which contain at least two mutations in the cationic site of the 40's loop and which, relative to the wild-type molecule, have a reduced GAG-binding activity. In particular it has been found that such mutated chemokines are effective in the treatment of multiple sclerosis and/or demyelinating diseases. A triple mutant of RANTES is the compound showing the best results.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.